HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hand Sanitizers Raise OTC Profile In US FDA’s Latest Drug Manufacturing Quality Report

Executive Summary

Widespread problems FDA found in hand sanitizers resulted from businesses unfamiliar with drug production entering the space after agency eased manufacturing standards to encourage increased supplies. Heartburn remedy ranitidine noted due to its chemical profile, not errors by manufacturers.

You may also be interested in...



Safe-T-Lite Ultraviolet Wand Causes Potential Unsafe Radiation Exposure Within Seconds

FDA advised Chinese firm Max-Lux Corp. that its Safe-T-Lite UV Wand was found in a July 2020 evaluation to be unsafe due to the absence of instructions for use. Typical use could expose consumers to unsafe levels of electronic product radiation.

Trade Groups Push US FDA To Close Window On Loosened OTC Sanitizer Production Standards

A day after FDA posted Scentsational’s recall announcement due to presence of benzene and acetaldehyde as well as methanol, American Cleaning Institute and Consumer Healthcare Products Association submit a letter urging FDA to restore order to OTC alcohol-based sanitizer market.

US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation

Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel